RxDoctor Payments Data

Bashar Markabawi, MD

Interventional Cardiology · Chandler, AZNPI 1518968429

Payments from drug & device makers

$11,830in general payments, 2019–2025

Across 530 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$789
  • Abbott$771
  • Bardy Diagnostics, Inc.$710
  • Actelion Pharmaceuticals US, Inc.$676
  • Boehringer Ingelheim$564
  • plus $7K from 43 others

What the payments were for

  • Food & beverage$11,06794%
  • Education$3613%
  • Other$4023%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,830 in reported general payments places this provider in the 45th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$640,393
Medicare patients
1,694
Services billed
7,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$383,019
XareltoRivaroxaban111$153,734
EntrestoSacubitril/Valsartan52$61,280
Repatha SureclickEvolocumab49$40,714
JardianceEmpagliflozin17$23,329
BrilintaTicagrelor29$19,526
MultaqDronedarone Hcl14$15,437
FarxigaDapagliflozin Propanediol12$12,954
Nebivolol Hcl69$5,465
Dabigatran EtexilateDabigatran Etexilate Mesylate15$4,949
Losartan Potassium390$3,606
Rosuvastatin Calcium276$3,470
Atorvastatin Calcium314$3,455
Ezetimibe117$3,059
Metoprolol Succinate214$2,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$385$383,019293 claims
Johnson & JohnsonXarelto$789$153,734111 claims
NovartisEntresto$1,127$61,28052 claims
AstraZenecaBrilinta, Farxiga$511$32,48141 claims
Boehringer IngelheimJardiance$564$23,32917 claims
Sanofi-aventis U.S. LLCMultaq$338$15,43714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →